Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I
Recruiting · NCT06503848 · Observational (researchers observe without assigning treatment) · Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute
View the official record on ClinicalTrials.gov →Interventions studied
Sumatriptan
What this trial is about
The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.
Who can take part
Age range
18 Years to 45 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Migraine with or without aura diagnosis according to ICHD-3 criteria
- \<8 migraine days per month
- Be able to read, write and understand instructions.
- Have internet access and mail address
- Signing of the informed consent
Exclusion criteria
- Active preventive treatment for migraine
- Active medication with an effect over the central nervous system
- Serious physical or psychiatric condition
- Cardiovascular or hepatic disease
- Pregnant or breastfeeding women
- Any triptan contraindication
- Severe migraine attacks without previous response to triptans or NSAIDs
Where it is running
1 location listed.
- Hospital Universitari Vall d'Hebron - Barcelona, Spain